Finally, TCR2 Therapeutics are evaluating a novel CAR design in which a mesothelin-specific scFv is directly fused to CD3ε, thereby incorporating the CAR into the endogenous T-cell receptor/CD3 complex (https://www.onclive.com/view/gavo-cel-elicits-clinical-benefit-in-solid-tumors-including-ovarian-cancer-and-mesothelioma, accessed on 15 December 2022). This evidence concerns the gene MSLN and ovarian carcinoma.